LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence
Introduction: The new LCP-formulation of tacrolimus (Tac) has shown pharmacokinetic advantages in patients after liver transplantation that are associated with better adherence. The influence of prolonged release Tac on adherence, trough levels and dosing of Tac remains unclear. Methods: A prospecti...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Transplantation Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451959623000148 |
| _version_ | 1797740500103462912 |
|---|---|
| author | Yvonne Schill Mario Schiffer Lars Pape |
| author_facet | Yvonne Schill Mario Schiffer Lars Pape |
| author_sort | Yvonne Schill |
| collection | DOAJ |
| description | Introduction: The new LCP-formulation of tacrolimus (Tac) has shown pharmacokinetic advantages in patients after liver transplantation that are associated with better adherence. The influence of prolonged release Tac on adherence, trough levels and dosing of Tac remains unclear. Methods: A prospective study was performed in 62 patients from two centers, who were switched to LCP-Tac after kidney transplantation, to assess adherence as defined by the Tac trough level coefficient of variation (CoV) (primary endpoint) and BAASIS© Score, as well as kidney function, Tac trough level and tacrolimus dose. Results: BAASIS© Score and Tac trough level CoV demonstrated good adherence over the study period, with no difference between the study timepoints (0.26 ± 0.16 at study start and 0.26 ± 0.11 at study end, p = 0.976, paired t-test). Graft function and Tac trough levels remained stable, and Tac dose could be reduced. Conclusions: A switch to LCP-Tac is feasible and leads to stable adherence, graft function and Tac trough levels, in combination with lower Tac doses. |
| first_indexed | 2024-03-12T14:13:18Z |
| format | Article |
| id | doaj.art-19064362545d4d40b3e52a77ed14e66a |
| institution | Directory Open Access Journal |
| issn | 2451-9596 |
| language | English |
| last_indexed | 2024-03-12T14:13:18Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Transplantation Reports |
| spelling | doaj.art-19064362545d4d40b3e52a77ed14e66a2023-08-21T04:20:23ZengElsevierTransplantation Reports2451-95962023-09-0183100139LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherenceYvonne Schill0Mario Schiffer1Lars Pape2Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, 30625 Hannover, GermanyDepartment of Nephrology, University Hospital of Erlangen, Erlangen, GermanyClinic of Pediatrics II, Essen University Hospital, Essen, Germany; Corresponding author at: Clinic of Pediatrics II, Essen University Hospital, Hufelandstrasse 55, 45147 Essen, Germany.Introduction: The new LCP-formulation of tacrolimus (Tac) has shown pharmacokinetic advantages in patients after liver transplantation that are associated with better adherence. The influence of prolonged release Tac on adherence, trough levels and dosing of Tac remains unclear. Methods: A prospective study was performed in 62 patients from two centers, who were switched to LCP-Tac after kidney transplantation, to assess adherence as defined by the Tac trough level coefficient of variation (CoV) (primary endpoint) and BAASIS© Score, as well as kidney function, Tac trough level and tacrolimus dose. Results: BAASIS© Score and Tac trough level CoV demonstrated good adherence over the study period, with no difference between the study timepoints (0.26 ± 0.16 at study start and 0.26 ± 0.11 at study end, p = 0.976, paired t-test). Graft function and Tac trough levels remained stable, and Tac dose could be reduced. Conclusions: A switch to LCP-Tac is feasible and leads to stable adherence, graft function and Tac trough levels, in combination with lower Tac doses.http://www.sciencedirect.com/science/article/pii/S2451959623000148TacrolimusKidney transplantationAdherenceTrough levelCoefficient of variationLCP |
| spellingShingle | Yvonne Schill Mario Schiffer Lars Pape LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence Transplantation Reports Tacrolimus Kidney transplantation Adherence Trough level Coefficient of variation LCP |
| title | LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence |
| title_full | LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence |
| title_fullStr | LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence |
| title_full_unstemmed | LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence |
| title_short | LCP-tacrolimus in long-term kidney graft recipients: Dosing and adherence |
| title_sort | lcp tacrolimus in long term kidney graft recipients dosing and adherence |
| topic | Tacrolimus Kidney transplantation Adherence Trough level Coefficient of variation LCP |
| url | http://www.sciencedirect.com/science/article/pii/S2451959623000148 |
| work_keys_str_mv | AT yvonneschill lcptacrolimusinlongtermkidneygraftrecipientsdosingandadherence AT marioschiffer lcptacrolimusinlongtermkidneygraftrecipientsdosingandadherence AT larspape lcptacrolimusinlongtermkidneygraftrecipientsdosingandadherence |